Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Exelixis reported a revenue of $597.76 million for the quarter ended September 2025, reflecting a year-over-year increase of 10.8% and an EPS of $0.78, up from $0.47 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $589 million by 1.49%, while the EPS surpassed the consensus estimate of $0.68 by 14.71% [1] Revenue Breakdown - Net product revenue was $542.93 million, exceeding the average estimate of $532.38 million by analysts, with a year-over-year increase of 13.6% [4] - Collaboration revenues reached $54.83 million, surpassing the estimated $50.78 million, marking a significant year-over-year increase of 4307.2% [4] - CABOMETYX generated $539.9 million in net product revenue, slightly above the average estimate of $538.89 million, with a year-over-year change of 13.5% [4] - COMETRIQ reported net product revenue of $3.1 million, compared to the average estimate of $3.17 million, reflecting a year-over-year increase of 29.2% [4] - License revenues from collaboration amounted to $56.24 million, exceeding the average estimate of $50.62 million [4] - Collaboration services revenues were reported at -$1.41 million, falling short of the estimated $1.42 million [4] Stock Performance - Exelixis shares have returned -4.9% over the past month, contrasting with the Zacks S&P 500 composite's increase of 2.1% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]